NCT06235814Completed
Molecular Analysis for Precision Surgery in Thyroid Cancer Trial
Molecular Analysis for Precision Surgery in Thyroid Cancer (MAPS) Trial
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investigators hypothesize that patients will 1) agree to preoperative molecular analysis, and 2) 50% of intermediate-risk patients will agree to and follow through with randomization. This will be a pilot study for a future randomized controlled trial (RTC) to compare between the two surgical approaches in intermediate-molecular risk thyroid cancer.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2 (actual)
- First submitted
- 18 Jan 2024
- Start date
- 19 Feb 2024
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Thyroid cancer
- NCT number
- NCT06235814
What you commit to
- Study type: Interventional
- Participants enrolled: 2
- From 19 Feb 2024 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior thyroid operation
Other illness
- Distant metastatic disease
Other
- Extrathyroidal extension or lymph node metastases seen on ultrasound
Who the study is looking for
- Patients aged 18 years or older at the time of enrollment
- English-speaking
- Bethesda V or VI thyroid nodule that are 1-4cm in size
- Bethesda III or IV nodules who underwent previously underwent Thyroseq molecular analysis that returned with intermediate molecular risk disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California, Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.